Amirhossein Farrokhzad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amirhossein Farrokhzad has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Amir Ali Judaki
Department of Cellular and Molecular Biology, Faculty of Sciences and Advanced Technology in Biology, University of Science and Culture, Tehran, Iran, usc.ac.ir
1 shared publication - Elham Rismani
Molecular Medicine Department, Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran
1 shared publication - Massoud Vosough
Royan Institute for Stem Cell Biology and Technology, ACECR
1 shared publication - Moustapha Hassan
Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
1 shared publication - Pedram Asadi Sarabi
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
1 shared publication - Zahra Hendi
Department of Cellular and Molecular Biology, Faculty of Sciences and Advanced Technology in Biology, University of Science and Culture, Tehran, Iran, usc.ac.ir
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Genomics
- Vol. 2026 (1)
Extracellular Matrix–Associated Biomarkers for Hepatocellular Carcinoma: Insights From Machine Learning and Single‐Cell Analysis
The 5‐year overall survival rate for hepatocellular carcinoma (HCC) patients remains below 20%. Alterations in the extracellular matrix (ECM) are increasingly recognized as central drivers of HCC initiation and progression. This study applied a system biology framework integrating omics data and machine learning to analyze gene expression and regulatory networks in HCC using The Cancer Genome Atlas. Eight ECM‐associated genes ( CSPG4 , CD34 , C1orf35 , ESM1 , MAPT , PLXDC1 , STC2 , and THBS4 ) were identified as upregulated diagnostic biomarkers with strong discriminatory power. Among them, MAPT , PLXDC1 , and STC2 showed significant associations with poor overall survival, defining a prognostic subset. Validation in the GSE104310 and GSE144269 datasets confirmed consistent expression patterns across cohorts. Functional enrichment linked these genes to tissue remodeling and angiogenesis. Single‐cell RNA sequencing revealed MAPT upregulation in T cells, PLXDC1 enrichment in cancer‐associated fibroblasts, and mild STC2 elevation in tumor‐associated macrophages and endothelial cells. These findings identify key ECM‐based biomarkers with potential for early detection, prognosis, and therapeutic targeting in HCC.
- 1 January 2026
- Published by Wiley in International Journal of Genomics
- Vol. 2026 (1)
Open AccessExtracellular Matrix–Associated Biomarkers for Hepatocellular Carcinoma: Insights From Machine Learning and Single‐Cell Analysis
The 5‐year overall survival rate for hepatocellular carcinoma (HCC) patients remains below 20%. Alterations in the extracellular matrix (ECM) are increasingly recognized as central drivers of HCC initiation and progression. This study applied a system biology framework integrating omics data and machine learning to analyze gene expression and regulatory networks in HCC using The Cancer Genome Atlas. Eight ECM‐associated genes ( CSPG4 , CD34 , C1orf35 , ESM1 , MAPT , PLXDC1 , STC2 , and THBS4 ) were identified as upregulated diagnostic biomarkers with strong discriminatory power. Among them, MAPT , PLXDC1 , and STC2 showed significant associations with poor overall survival, defining a prognostic subset. Validation in the GSE104310 and GSE144269 datasets confirmed consistent expression patterns across cohorts. Functional enrichment linked these genes to tissue remodeling and angiogenesis. Single‐cell RNA sequencing revealed MAPT upregulation in T cells, PLXDC1 enrichment in cancer‐associated fibroblasts, and mild STC2 elevation in tumor‐associated macrophages and endothelial cells. These findings identify key ECM‐based biomarkers with potential for early detection, prognosis, and therapeutic targeting in HCC.